***Medarex to Receive Milestone Payment from Amgen***Product to Enter Clinical Trials - 500 Beiträge pro Seite
eröffnet am 29.11.04 13:15:21 von
neuester Beitrag 29.11.04 14:09:42 von
neuester Beitrag 29.11.04 14:09:42 von
Beiträge: 6
ID: 930.429
ID: 930.429
Aufrufe heute: 0
Gesamt: 1.433
Gesamt: 1.433
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 46 Minuten | 11255 | |
| vor 20 Minuten | 7850 | |
| heute 19:17 | 3908 | |
| vor 25 Minuten | 3275 | |
| vor 19 Minuten | 2640 | |
| vor 26 Minuten | 2073 | |
| vor 12 Minuten | 2004 | |
| heute 19:54 | 1751 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.507,99 | +0,35 | 296 | |||
| 2. | 4. | 4,2500 | +7,19 | 123 | |||
| 3. | 2. | 163,02 | -1,40 | 104 | |||
| 4. | 3. | 10,140 | -4,88 | 104 | |||
| 5. | 6. | 0,1960 | +3,70 | 85 | |||
| 6. | Neu! | 1,1800 | +2,34 | 58 | |||
| 7. | 12. | 0,9600 | -14,29 | 53 | |||
| 8. | 11. | 5,9940 | -1,28 | 46 |
Feedback
MEDAREX - MEDX (Nasdaq)- 883 040
akt.: 8,12€
Klasse Chart (s.u.) - HEUTE "großer" Ausbruch? (deutlich >11$)
Press Release Source: Medarex, Inc.
Medarex to Receive Milestone Payment from Amgen; 21st UltiMAb(R) Product to Enter Clinical Trials
Monday November 29, 6:00 am ET
PRINCETON, N.J., Nov. 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) today announced that it will receive an undisclosed milestone payment from its licensing partner, Amgen Inc., for the advancement of an antibody into clinical trials.](red] The antibody product was developed using Medarex`s UltiMAb® technology and is the second UltiMAb-derived antibody in clinical development by Amgen. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development.
ADVERTISEMENT
"We are pleased that our partnership with Amgen, a leading biotechnology company, continues to advance. We look forward to the continued progress that these efforts make toward the development of fully human antibodies as an innovative therapeutic class and addressing important medical needs," said Donald L. Drakeman, President and CEO of Medarex.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery and development of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Twenty-one of these therapeutic products derived from Medarex technology are currently in human clinical testing, with the most advanced product presently in a Phase III clinical trial. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world`s unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.
Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential;" "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties associated with the collaborative process, uncertainties related to product manufacturing as well as risks detailed from time to time in Medarex`s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2003 and subsequent Quarterly Reports on Form 10-Q. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex`s public disclosure filings are available from its investor relations department.
Medarex®, the Medarex logo and UltiMAb® are registered trademarks of Medarex, Inc. All rights are reserved.
--------------------------------------------------------------------------------
akt.: 8,12€
Klasse Chart (s.u.) - HEUTE "großer" Ausbruch? (deutlich >11$)
Press Release Source: Medarex, Inc.
Medarex to Receive Milestone Payment from Amgen; 21st UltiMAb(R) Product to Enter Clinical Trials
Monday November 29, 6:00 am ET
PRINCETON, N.J., Nov. 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) today announced that it will receive an undisclosed milestone payment from its licensing partner, Amgen Inc., for the advancement of an antibody into clinical trials.](red] The antibody product was developed using Medarex`s UltiMAb® technology and is the second UltiMAb-derived antibody in clinical development by Amgen. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development.
ADVERTISEMENT
"We are pleased that our partnership with Amgen, a leading biotechnology company, continues to advance. We look forward to the continued progress that these efforts make toward the development of fully human antibodies as an innovative therapeutic class and addressing important medical needs," said Donald L. Drakeman, President and CEO of Medarex.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery and development of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Twenty-one of these therapeutic products derived from Medarex technology are currently in human clinical testing, with the most advanced product presently in a Phase III clinical trial. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world`s unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.
Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential;" "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties associated with the collaborative process, uncertainties related to product manufacturing as well as risks detailed from time to time in Medarex`s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2003 and subsequent Quarterly Reports on Form 10-Q. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex`s public disclosure filings are available from its investor relations department.
Medarex®, the Medarex logo and UltiMAb® are registered trademarks of Medarex, Inc. All rights are reserved.
--------------------------------------------------------------------------------
eben schon 8,30€ (500 Stück)
USA pre-market: 10,80$
USA pre-market: 10,80$
Das sind Klasse NEWS (#1) und ein toller Chart 
Trading Spotlight
akt. 10,90$ => 8,23€ 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 296 | ||
| 123 | ||
| 104 | ||
| 104 | ||
| 85 | ||
| 58 | ||
| 53 | ||
| 46 | ||
| 43 | ||
| 42 |
| Wertpapier | Beiträge | |
|---|---|---|
| 38 | ||
| 32 | ||
| 27 | ||
| 26 | ||
| 25 | ||
| 22 | ||
| 22 | ||
| 19 | ||
| 19 | ||
| 16 |
